MabThera 500 mg concentrate for solution for infusion clinical trials
9 indexed studies · 0 currently recruiting
- AuthorisedPhase II and Phase III (Integrated)
Evaluation of Glucocorticoids plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA vasculitis: A Prospective, randomized, controlled, double-blind study
This study looks at new treatments for IgA vasculitis (IgAV), focusing on using specific medications (Rituximab or Rixathon) with standard steroid treatment. The aim is to see if these combinations can help patients get into remission and stay there, reducing the need for steroids.
For: Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV.France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
This study is for adults with a type of lymphoma called DLBCL that has come back or not responded to earlier treatment. It compares two treatments: a standard one (R-ICE) and a new one (Pola-R-ICE) to see which is better at stopping the cancer from growing.
For: Adult patients with relapsed or primary refractory DLBCLSpain · Austria · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination, Polivy plus R-GEMOX, for adults with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this combination to R-GEMOX alone, checking for safety and how well it works.
For: Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Italy · Germany · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.
For: Chronic Lymphocytic Leukemia (CLL)Spain · France · Italy - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.
For: Primary or Secondary Progressive Multiple SclerosisGermany · Italy · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)
This study is looking at a new way to treat a type of cancer called MALT lymphoma. It combines two medicines, chlorambucil and rituximab, given in a drip and under the skin, to see how well they work together and if they cause many side effects.
For: Extranodal Marginal Zone LymphomaFrance · Italy - AuthorisedTherapeutic confirmatory (Phase III)
Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study
This study looks at whether a medicine called rituximab, given with salt water, can help people in the UK with a nerve condition called anti-MAG neuropathy. Researchers want to see if it improves their symptoms over 12 months.
For: anti-MAG neuropathyFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
This study is testing a new way to treat a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares a potential new drug combination with a standard one to see if it works better and is safe for people newly diagnosed with this condition.
For: Previously Untreated Diffuse large B-cell lymphoma (DLBCL)Belgium · Poland · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial
This study looks at a new combination of medicines (MabThera, Polivy, and Bendamustin) for people with a type of blood cancer called mantle cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective this treatment is.
For: Mantle cell lymphomaAustria